A Biden spokeswoman confirmed the former president finished several weeks of radiation therapy treatment Monday.

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today presents on the positive interim efficacy data from its ongoing ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

A new branch of a national cancer charity has opened in the grounds of a town's hospital. The Maggie's Centre will offer ...

A novel combination of already approved drugs has shown a 40.3% reduction in death risk from advanced recurring prostate cancer in a long-term trial.

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by Dr. Channing Paller discussing germline and somatic genetic ...

When a patient finishes cancer treatment, the majority of cancer treatment facilities encourage them to ring a bell that is ...

Biden announced in May that he had an advanced stage of prostate cancer that has metastasized, or spread, to his bones, ...